ARTICLE | Regulation
Interim readout coming soon in Wolfram syndrome, with PSP data due next year; second ALS candidate also moving forward
By Paul Bonanos, Director of Biopharma Intelligence
April 4, 2024 7:12 PM UTC
In the wake of a clinical failure, Amylyx will be a much smaller company as it withdraws its ALS drug from two markets and looks ahead to its next catalyst this month.
Weeks after Relyvrio/Albrioza (AMX0035) missed the primary endpoint and secondary endpoints in the confirmatory Phase III PHOENIX study to treat amyotrophic lateral sclerosis, Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is laying off 70% of its employees and beginning the process of discontinuing the drug’s authorizations in the U.S. and Canada…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652002/amylyx-facing-future-as-it-downsizes-begins-withdrawal-of-als-drug